Modality
Gene Therapy
MOA
Menini
Target
TNFα
Pathway
Amyloid
SLEAtopic Derm
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
~Feb 2023
→ ~May 2024
Phase 2
Aug 2024
→ Jul 2031
Phase 2Current
NCT03657781
467 pts·Atopic Derm
2024-11→2026-03·Recruiting
NCT05060736
823 pts·SLE
2024-08→2031-07·Terminated
1,290 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-083w agoPh3 Readout· Atopic Derm
2031-07-165.3y awayPh3 Readout· SLE
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Termina…
P2/3
Recruit…
Catalysts
Ph3 Readout
2026-03-08 · 3w ago
Atopic Derm
Ph3 Readout
2031-07-16 · 5.3y away
SLE
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03657781 | Phase 2/3 | Atopic Derm | Recruiting | 467 | Biomarker |
| NCT05060736 | Phase 2/3 | SLE | Terminated | 823 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| VKT-4052 | Viking Therapeutics | Phase 2/3 | TNFα | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |